

**Endometriosis targeted MRI imaging using bevacizumab-modified nanoparticles
aiming at vascular endothelial growth factor**

Qi Zhang M.D. Ph.D. *, Shiman Wu M.D. Ph.D. *, Yajie Li, BM, Mao Lai, BM, Qing

Li, Ph. D. , Caixia Fu, Ph. D. , Zhenwei Yao M.D. Ph.D.#, Junhai Zhang M.D. Ph.D.#




Figure S1. Dynamic light scattering (DLS) distribution curve of NaGdF₄@PEG-cholesterol@bevacizumab-Cy5.5 nanoparticles (NPBCNs).




Figure S2. CCK8 assay of NaGdF₄@PEG-cholesterol@bevacizumab-Cy5.5 nanoparticles on hEM15A cells




Figure S3. *In vivo* toxicity evaluation of NaGdF₄@PEG-cholesterol@bevacizumab-Cy5.5 nanoparticles. a) Hematological indices and b) hematoxylin and eosin (H&E) staining of major organs of rat after injection of NaGdF₄@PEG-cholesterol@bevacizumab-Cy5.5 nanoparticles for 3 days and 60 days.